Table 2 Tumor characteristics
All patients (n = 282) | Patients without visceral metastasis (n = 220) | Patients with visceral metastasis (n = 62) | |||
|---|---|---|---|---|---|
Curative treatment (n = 151) | BSC (n = 69) | Palliative treatment (n = 30) | BSC (n = 32) | ||
Tumoral stage | |||||
stage I | 27 (9.7%) | 24 (15.9%) | 3 (4.3%) | - | - |
stage II | 68 (24.5%) | 61 (40.4%) | 7 (10.1%) | - | - |
stage III | 69 (24.9%) | 51 (33.8%) | 18 (26.1%) | - | - |
stage IV (M1a) | 8 (2.9%) | 7 (4.6%) | 1 (1.4%) | - | - |
stage IV (M1b) | 62 (22.4%) | - | - | 30 (100%) | 32 (100%) |
unknown but M0 | 48 (17.0%) | 8 (5.3%) | 40 (58.0%) | - | - |
Tumoral location | |||||
lower third | 151 (53.5%) | 80 (60.0%) | 37 (53.6%) | 19 (63.3%) | 15 (46.9%) |
middle third | 86 (30.6%) | 44 (29.1%) | 21 (30.4%) | 9 (30.0%) | 12 (37.5%) |
upper third | 45 (16.0%) | 27 (17.9%) | 11 (15.9%) | 2 (6.7%) | 5 (15.6%) |
Mean tumor length † (n = 199, cm, SD) | 5.2 ± 2.5 | 4.7 ± 2.3 | 5.4 ± 2.6 | 5.9 ± 1.8 | 7.2 ± 3.2 |
Tumor length ≥ 5 cm † | 116/199 (58.3%) | 66/124 (53.2%) | 25/43 (58.1%) | 11/14 (78.6%) | 14/18 (77.8%) |
Mean tumor diameter † (n = 81, cm, SD) | 2.7 ± 1.3 | 2.6 ± 1.2 | 4.1 ± 1.2 * | 2.5 ± 0.7 | 1.9 ± 0.1 |
Histological type † (n = 271) | |||||
SCC | 183 (67.5%) | 103 (70.1%) | 45 (70.3%) | 17 (56.7%) | 18 (60.0%) |
adenocarcinoma | 83 (30.6%) | 44 (29.9%) | 18 (28.1%) | 12 (40.0%) | 9 (30.0%) |
other | 5 (1.8%) | 0 | 1 (1.5%) | 1 (3.3%) | 3 (10.0%) |